Lyme disease, Challenges & The DebateLyme illness is the most common tick-borne disease in the U.S. And Europe, slow-growing bacteria called Borrelia. The disease can drastically different results for different people. Symptoms range from debilitating disease to no symptoms.
The study, which was funded by a grant for for Lyme Disease research, could also potentially offer answers to other immune-based diseases, including HIV / AIDS. The team the study highlights the the study highlights the long-standing and controversial debate in the medical community to settle on methods of treatment.. Source Haig Keledjian Viral GeneticsViral Genetics , a biotechnology company that discovers and develops immune-based therapies, today announced to the general public preliminary results of the ongoing Lyme Disease study.The U.S. Advisory says there support the approved Exubera Pfizer, the world’s largest pharmaceutical business manufactures. The panel voted 7-2 favor of the new drug. The FDA tends to go along to what the Panel advise.
CombinatoRx, Incorporated today announced that that U.S. Food and Drug Administration , the Prescription Drug User Fee Act target date for verification of the EXALGO extended-release tablets New Drug Application by Monday 22 February 2010 to Monday, 1 Mar. 2010 because government ren. Type of 1 or 2 diabetics might benefit from this new way of administration of their insulin.